This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs immuno-therapy medical pharmaceuticals
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
NVSPositive Net Change RHHBYNegative Net Change PFEPositive Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
by Zacks Equity Research
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change
medical pharmaceuticals
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day.
AMZNPositive Net Change HTZPositive Net Change LLYPositive Net Change GOOGLPositive Net Change SHOPPositive Net Change
pharmaceuticals
Bull of the Day: Eli Lilly (LLY)
by Ethan Feller
Eli Lilly stock boasts both defensive and growth characteristics
LLYPositive Net Change
medical pharmaceuticals
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
by Zacks Equity Research
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
REGNNegative Net Change SNYNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
by Zacks Equity Research
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
AZNNegative Net Change GSKPositive Net Change BIIBPositive Net Change IONSPositive Net Change
medical pharmaceuticals
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
BMYNegative Net Change MRKNegative Net Change CRVSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Stock Reports for Visa, AbbVie & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
VPositive Net Change MCONegative Net Change LLYPositive Net Change BUDPositive Net Change KMIPositive Net Change ABBVNegative Net Change SVTPositive Net Change UGNegative Net Change
business-services consumer-staples medical multi-sector-conglomerates pharmaceuticals
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
by Zacks Equity Research
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
MRKNegative Net Change SMMTPositive Net Change FULCPositive Net Change BVSPositive Net Change
medical pharmaceuticals
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
AZNNegative Net Change NVSPositive Net Change PFEPositive Net Change RLAYPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
RHHBYNegative Net Change MRKNegative Net Change LLYPositive Net Change SMMTPositive Net Change
pharmaceuticals
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
by Zacks Equity Research
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
REGNNegative Net Change NVSPositive Net Change LLYPositive Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
by Zacks Equity Research
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
NVSPositive Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
by Zacks Equity Research
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
REGNNegative Net Change SNYNegative Net Change AZNNegative Net Change GSKPositive Net Change
pharmaceuticals
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
by Zacks Equity Research
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change IMVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Analyst Reports for Amazon.com, Roche & GE Aerospace
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Roche Holding AG (RHHBY) and GE Aerospace (GE), as well as two micro-cap stocks Canterbury Park Holding Corporation (CPHC) and NVE Corporation (NVEC).
AMZNPositive Net Change GEPositive Net Change RHHBYNegative Net Change DFSPositive Net Change CVEPositive Net Change NVECPositive Net Change IQVPositive Net Change CPHCNo Net Change
consumer-discretionary multi-sector-conglomerates pharmaceuticals retail semiconductor transportation
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
by Zacks Equity Research
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
SNYNegative Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
by Zacks Equity Research
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
ILMNPositive Net Change KRYSPositive Net Change HOTHPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
by Kinjel Shah
European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
SNYNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYPositive Net Change
pharmaceuticals
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
by Zacks Equity Research
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
NVSPositive Net Change VYGRPositive Net Change KRYSPositive Net Change FULCPositive Net Change
gene-therapy medical pharmaceuticals
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
by Zacks Equity Research
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
BMRNPositive Net Change ARCTNegative Net Change FULCPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
by Zacks Equity Research
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
REGNNegative Net Change RHHBYNegative Net Change MRKNegative Net Change BAYRYNegative Net Change
biotechs medical pharmaceuticals